Ascendis aiming to become market leader
Ascendis Pharma, which received FDA approval for its weekly administered growth hormone Skytrofa from the FDA on Wednesday, is striving for market leadership, says Jesper Høiland, Global Commercial Officer at the company.
BY ANDREAS LØNSTRUP, TRANSLATED BY CATHERINE BRETT
Ascendis Pharma has announced that it aims to become a market leader, Danish financial daily Børsen reports.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
FDA approves Ascendis' weekly growth hormone
For subscribers
Ascendis increases expenses shortly before moment of truth
For subscribers
.jpg&w=384&q=75)
